Find, compare & contact
Cinnamaldehyde
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Cinnamaldehyde API 14371-10-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Cinnamaldehyde. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Cinnamaldehyde
- Synonyms:
- (3E)-3-phenylprop-2-enal , (E)-3-Phenyl-2-propenal , (E)-3-Phenyl-propenal , (E)-3-Phenylpropenal , 3-phenylacrylaldehyde , Cinnamal , trans-trans-Cinnamic aldehyde , Zimtaldehyde
- Cas Number:
- 14371-10-9
- DrugBank number:
- DB14184
- Unique Ingredient Identifier:
- SR60A3XG0F
General Description:
Cinnamaldehyde, identified by CAS number 14371-10-9, is a notable compound with significant therapeutic applications. Cinnamaldehyde is a naturally occurring flavonoid that gives the spice cinnamon its flavour and odour. It occurs naturally in the bark of cinnamon trees and other species of the genus Cinnamomum such as camphor and cassia. Sensitivity to cinnamaldehyde may be identified with a clinical patch test.
Indications:
This drug is primarily indicated for: Cinnamaldehyde is approved by the FDA for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis (ACD) in persons 6 years of age and older. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Absorption:
The absorption characteristics of Cinnamaldehyde are crucial for its therapeutic efficacy: Cinnamaldehyde is 52% absorbed through the skin and shown to be rapidly absorbed from the gut . The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Route of Elimination:
The elimination of Cinnamaldehyde from the body primarily occurs through: Cinnamaldehyde is metabolized and excreted primarily in the urine and, to a minor extent, in the feces . After oral or intraperitoneal administration to rats and mice, 69–98% of the dose of cinnamaldehyde was recovered in the urine and feces within 24 h . Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Classification:
Cinnamaldehyde belongs to the class of organic compounds known as cinnamaldehydes. These are organic aromatic compounds containing a cinnamlaldehyde moiety, consisting of a benzene and an aldehyde group to form 3-phenylprop-2-enal, classified under the direct parent group Cinnamaldehydes. This compound is a part of the Organic compounds, falling under the Phenylpropanoids and polyketides superclass, and categorized within the Cinnamaldehydes class, specifically within the None subclass.
Categories:
Cinnamaldehyde is categorized under the following therapeutic classes: Aldehydes, Antimutagenic Agents, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Cell-mediated Immunity, Compounds used in a research, industrial, or household setting, Diet, Food, and Nutrition, Drugs that are Mainly Renally Excreted, Flavoring Agents, Food, Food Additives, Food Ingredients, Increased Histamine Release, Pharmaceutic Aids, Pharmaceutical Preparations, Physiological Phenomena, Protective Agents, Standardized Chemical Allergen. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Cinnamaldehyde is a type of Antineoplastics
Antineoplastics are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) primarily used in the treatment of cancer. These powerful substances inhibit or destroy the growth of cancer cells, thus impeding the progression of malignancies.
Antineoplastics exert their therapeutic effects through various mechanisms. Some APIs interfere with DNA replication, inhibiting the division and proliferation of cancer cells. Others target specific proteins or enzymes involved in tumor growth, effectively blocking their function. Additionally, certain antineoplastic agents induce programmed cell death, known as apoptosis, in cancer cells.
These APIs find application in a wide range of cancer treatments, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy. They are often administered in combination with other drugs to optimize therapeutic outcomes and minimize drug resistance.
Antineoplastics are typically synthesized through complex chemical processes, ensuring high purity and potency. Stringent quality control measures are implemented throughout manufacturing to meet regulatory standards and ensure patient safety.
Although antineoplastics offer significant benefits in treating cancer, they can also cause adverse effects due to their cytotoxic nature. Common side effects include bone marrow suppression, gastrointestinal disturbances, hair loss, and immune system suppression. Close monitoring and supportive care are essential to manage these side effects effectively.
In conclusion, antineoplastics are a vital category of pharmaceutical APIs used in the treatment of cancer. Through their diverse mechanisms of action, these compounds play a critical role in combating malignancies and improving patient outcomes.
